1. Home
  2. HY vs ADCT Comparison

HY vs ADCT Comparison

Compare HY & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hyster-Yale Materials Handling Inc.

HY

Hyster-Yale Materials Handling Inc.

HOLD

Current Price

$33.41

Market Cap

507.5M

Sector

Industrials

ML Signal

HOLD

Logo ADC Therapeutics SA

ADCT

ADC Therapeutics SA

HOLD

Current Price

$3.57

Market Cap

439.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HY
ADCT
Founded
1991
2011
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Construction/Ag Equipment/Trucks
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
507.5M
439.8M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
HY
ADCT
Price
$33.41
$3.57
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$7.60
AVG Volume (30 Days)
88.2K
565.6K
Earning Date
02-24-2026
11-10-2025
Dividend Yield
4.29%
N/A
EPS Growth
N/A
N/A
EPS
0.15
N/A
Revenue
$3,913,600,000.00
$75,209,000.00
Revenue This Year
N/A
$12.48
Revenue Next Year
N/A
$5.12
P/E Ratio
$218.68
N/A
Revenue Growth
N/A
6.35
52 Week Low
$26.41
$1.05
52 Week High
$57.89
$4.80

Technical Indicators

Market Signals
Indicator
HY
ADCT
Relative Strength Index (RSI) 53.90 46.33
Support Level $32.27 $3.48
Resistance Level $35.08 $3.87
Average True Range (ATR) 1.36 0.21
MACD 0.16 0.02
Stochastic Oscillator 64.44 37.25

Price Performance

Historical Comparison
HY
ADCT

About HY Hyster-Yale Materials Handling Inc.

Hyster Yale Inc designs, engineers, manufactures, sells and services a comprehensive line of lift trucks, attachments, aftermarket parts and technology solutions marketed globally under the Hyster and Yale brand names. The Company has five segments, which include three in the lift truck business as discussed below, as well as Bolzoni S.p.A. (Bolzoni) and Nuvera Fuel Cells, LLC (Nuvera). Majority of revenue is from Lift Trucks. geographically operates in America, EMEA, JAPIC, maximum revenue from America.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Share on Social Networks: